Elotuzumab(Synonyms: Empliciti; HuLuc 63; PDL 063; BMS 901608)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Elotuzumab (Synonyms: Empliciti; HuLuc 63; PDL 063; BMS 901608)

Elotuzumab 是一种针对 SLAMF7 受体的单克隆抗体。当作为复发或难治性多发性骨髓瘤 (RRMM) 的单一药物给予时,Elotuzumab 没有显着的抗骨髓瘤活性。与其他抗骨髓瘤药物联合使用时,Elotuzumab 可改善反应和结果。

Elotuzumab(Synonyms: Empliciti;  HuLuc 63;  PDL 063;  BMS 901608)

Elotuzumab Chemical Structure

CAS No. : 915296-00-3

规格 价格 是否有货
1 mg ¥2800 询问价格 & 货期
5 mg ¥8500 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents[1].

CAS 号

915296-00-3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Magen H, et al. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. Ther Adv Hematol. 2016;7(4):187-195.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务